- Investing Ideas
- U.K. Pharmaceuticals & Biotech Pure Equity Growth
U.K. Pharmaceuticals & Biotech Pure Equity Growth
Results
9
Companies that has zero debt on their balance sheet and is forecast to grow at an exponential rate in the future.
9 companies
Corcept Therapeutics
Market Cap: US$9.7b
A biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
0I3Q
US$91.38
7D
3.5%
1Y
30.2%
Camurus
Market Cap: SEK 37.4b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMXS
SEK 615.75
7D
9.2%
1Y
-12.0%
Camurus
Market Cap: SEK 37.4b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
0RD1
SEK 616.25
7D
14.7%
1Y
-12.9%
BioArctic
Market Cap: SEK 26.6b
Develops biological drugs for patients with central nervous system disorders in Sweden.
BIOABS
SEK 328.70
7D
0%
1Y
n/a
BioArctic
Market Cap: SEK 26.6b
Develops biological drugs for patients with central nervous system disorders in Sweden.
0RV2
SEK 299.30
7D
-4.5%
1Y
52.8%
Bonesupport Holding
Market Cap: SEK 13.2b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BONEXS
SEK 219.70
7D
-7.6%
1Y
-30.6%
Bonesupport Holding
Market Cap: SEK 13.2b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
0RQO
SEK 199.20
7D
-15.8%
1Y
-38.8%
Kuros Biosciences
Market Cap: CHF 818.4m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
KURNz
CHF 20.84
7D
-1.8%
1Y
-25.3%
Kuros Biosciences
Market Cap: CHF 818.4m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
0RHR
CHF 19.53
7D
-8.0%
1Y
-30.0%